ATEZOLIZUMAB (Tecentriq) prior authorization at Regence
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Regence requires Programmed Death Receptor-1 Blocking Antibody prior-authorization documentation for ATEZOLIZUMAB (Tecentriq): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Regence reviews ATEZOLIZUMAB (Tecentriq) prior authorizations against its medical policy for Programmed Death Receptor-1 Blocking Antibody. Regence-specific context: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Programmed Death Receptor-1 Blocking Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Regence's medical policy URL referenced in the cover letter
Regence's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Cross-state coordination for multi-state members (OR/WA/ID/UT)
- Step therapy via Prime Therapeutics
- Behavioral health network adequacy
- Specialty drug PA
ATEZOLIZUMAB (Tecentriq)-specific denial patterns and context
Across payers (not just Regence), ATEZOLIZUMAB (Tecentriq)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Triple-negative breast cancer indication (voluntarily withdrawn 2021 — plans cite this for all TNBC denials)
- SCLC maintenance denial
- Off-label NSCLC combinations
Brand: Tecentriq. PD-L1 inhibitor. SubQ formulation (Tecentriq Hybreza) FDA-approved September 2024. Note: TNBC accelerated approval withdrawn August 2021 — be careful citing this indication in appeals.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when a Regence denial sticks and the patient needs bridge access while appealing.
How Regence approaches Immune checkpoint inhibitors PAs
Regence's Immune checkpoint inhibitors reviewer typically anchors ATEZOLIZUMAB (TECENTRIQ) prior-auth decisions on specialty drug pa. Pharmacy-benefit review for ATEZOLIZUMAB (TECENTRIQ) at Regence is routed through Prime Therapeutics. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Off-label oncology appeals at Regence carry significantly higher reversal rates when the appeal letter cites the specific NCCN compendium evidence-block category (2A or above) rather than peer-reviewed citations alone. Regence is domiciled in OR, so unresolved appeals escalate to the OR insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.
If the PA is denied
Regence gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.regence.com/provider) with the same packet plus a peer-reviewed citation supporting ATEZOLIZUMAB (Tecentriq)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Regence denial on DenialHelp.
Contact Regence
- Provider portal: https://www.regence.com/provider
Frequently asked questions
What documentation does Regence need for ATEZOLIZUMAB (Tecentriq) prior auth?
Regence's typical PA packet for ATEZOLIZUMAB (Tecentriq): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Programmed Death Receptor-1 Blocking Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Regence?
Standard ATEZOLIZUMAB (Tecentriq) PA decisions at Regence: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Regence most often reject ATEZOLIZUMAB (Tecentriq) for?
Across Regence's book the common rejection patterns include: Cross-state coordination for multi-state members (OR/WA/ID/UT); Step therapy via Prime Therapeutics; Behavioral health network adequacy. For ATEZOLIZUMAB (Tecentriq) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Does Regence cover off-label use of ATEZOLIZUMAB (TECENTRIQ) supported by NCCN compendium?
Regence generally follows the NCCN Drugs & Biologics Compendium for oncology coverage — Category 1, 2A, and most 2B recommendations are reimbursable in most plans under Medicare-aligned and many commercial policies. For off-label ATEZOLIZUMAB (TECENTRIQ), cite the NCCN compendium entry by version + table number, name the evidence-block category, and attach the specific clinical-trial or meta-analysis reference. 30-day decision; 180 days to appeal if denied. Adjuvant and combination uses face heavier scrutiny than first-line metastatic. Pharmacy-benefit handling is routed through Prime Therapeutics. External-review escalation for Regence fully-insured policies sits with the OR insurance department.
How do I prep for a peer-to-peer with Regence on ATEZOLIZUMAB (Tecentriq)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the ATEZOLIZUMAB (Tecentriq) PA packet
Open ApprovalHelp — generate a ATEZOLIZUMAB (Tecentriq) prior-auth packet tailored to Regence's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com